BKBenjamin Küpper

Benjamin Küpper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Küpper has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Rolf Wichmann

    Kernforschungsanlage Jülich, Institut für Biotechnologie, Postfach 1913, D‐5170 Jülich, West Germany

    3 shared publications
  • Lars Matthias Blank

    Institute of Applied Microbiology – iAMB, Aachen Biology and Biotechnology – ABBt, Worringer Weg 1, RWTH Aachen University, D-52074, Aachen, Germany

    2 shared publications
  • Till Tiso

    Institute of Applied Microbiology RWTH Aachen University Aachen Germany

    2 shared publications
  • A. Imhoff

    TU Dortmund, Fakultät Bio- und Chemieingenieurwesen, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge-Straße 66, D-44227 Dortmund, Germany

    1 shared publication
  • A. Mause

    TU Dortmund, Fakultät Bio- und Chemieingenieurwesen, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge-Straße 66, D-44227 Dortmund, Germany

    1 shared publication
  • Adam Imhoff

    Technische Universität Dortmund, Arbeitsgruppe Bioverfahrenstechnik, Emil-Figge Straße 66, 44227 Dortmund, Germany

    1 shared publication

Latest Publications

  • Methods for Recombinant Rhamnolipid Production

    by Till Tiso, Andrea Germer, Benjamin Küpper, Rolf Wichmann, Lars M. Blank


  • Fermentative Production of Monorhamnolipids in Pilot Scale – Challenges in Scale‐Up

    by Benjamin Küpper, Anika Mause, Lisa Halka, Adam Imhoff, Christian Nowacki, Rolf Wichmann

    Die fermentative Herstellung von Biotensiden wird meist durch die exzessive Bildung von stabilem Schaum erschwert. Am Beispiel von Monorhamnolipiden werden Vorschläge sowohl zur stabilen Aufrechterhaltung von begasten und gerührten Fermentationen wie auch zur Isolierung dieser Biotenside im größeren Maßstab gegeben, da diese kommerziell nur in sehr kleinen Mengen erhältlich sind. Ein besonderer Fokus liegt dabei auf der Verwendung nachwachsender Rohstoffe.


  • Open Access

    Fermentative Herstellung und Aufarbeitung von Monorhamnolipiden

    by B. Küpper, L. Halka, A. Imhoff, A. Mause, R. Wichmann

  • Open Access

    Growth independent rhamnolipid production from glucose using the non-pathogenic Pseudomonas putida KT2440

    by Andreas Wittgens, Till Tiso, Torsten T Arndt, Pamela Wenk, Johannes Hemmerich, Carsten Müller, Rolf Wichmann, Benjamin Küpper, Michaela Zwick, Susanne Wilhelm, et al.

    Background: Rhamnolipids are potent biosurfactants with high potential for industrial applications. However, rhamnolipids are currently produced with the opportunistic pathogen Pseudomonas aeruginosa during growth on hydrophobic substrates such as plant oils. The heterologous production of rhamnolipids entails two essential advantages: Disconnecting the rhamnolipid biosynthesis from the complex quorum sensing regulation and the opportunity of avoiding pathogenic production strains, in particular P. aeruginosa. In addition, separation of rhamnolipids from fatty acids is difficult and hence costly. Results: Here, the metabolic engineering of a rhamnolipid producing Pseudomonas putida KT2440, a strain certified as safety strain using glucose as carbon source to avoid cumbersome product purification, is reported. Notably, P. putida KT2440 features almost no changes in growth rate and lag-phase in the presence of high concentrations of rhamnolipids (> 90 g/L) in contrast to the industrially important bacteria Bacillus subtilis, Corynebacterium glutamicum, and Escherichia coli. P. putida KT2440 expressing the rhlAB-genes from P. aeruginosa PAO1 produces mono-rhamnolipids of P. aeruginosa PAO1 type (mainly C10:C10). The metabolic network was optimized in silico for rhamnolipid synthesis from glucose. In addition, a first genetic optimization, the removal of polyhydroxyalkanoate formation as competing pathway, was implemented. The final strain had production rates in the range of P. aeruginosa PAO1 at yields of about 0.15 g/gglucose corresponding to 32% of the theoretical optimum. What's more, rhamnolipid production was independent from biomass formation, a trait that can be exploited for high rhamnolipid production without high biomass formation. Conclusions: A functional alternative to the pathogenic rhamnolipid producer P. aeruginosa was constructed and characterized. P. putida KT24C1 pVLT31_rhlAB featured the highest yield and titer reported from heterologous rhamnolipid producers with glucose as carbon source. Notably, rhamnolipid production was uncoupled from biomass formation, which allows optimal distribution of resources towards rhamnolipid synthesis. The results are discussed in the context of rational strain engineering by using the concepts of synthetic biology like chassis cells and orthogonality, thereby avoiding the complex regulatory programs of rhamnolipid production existing in the natural producer P. aeruginosa.